Stockscreener 앱 받기
153.31
0.39%
0.74
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Zacks Investment ResearchGlobes - Globes - Israel Business News
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
GlobesIsrael Business News - גלובס
Neurocrine Biosciences Rings the Nasdaq Stock Market Opening Bell - Nasdaq
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance
Neurocrine Biosciences Rings the Opening Bell - Nasdaq
Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus
S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.6% -- What GF Sc - GuruFocus
Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com
Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.4% -- What GF Sc - GuruFocus
Why is Neurocrine Biosciences stock sliding today? By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) Dips 3%: Stock Holds Above Key Support at $156.99Quality Factor - Vinanet
Why Neurocrine Biosciences (NBIX) Stock Is Down Today - Quiver Quantitative
What's Going On With Neurocrine Biosciences Stock On Wednesday? - Benzinga
Neurocrine down on safety events linked to Vykat (NBIX:NASDAQ) - Seeking Alpha
Neurocrine Biosciences Shares Drop Amid Vykat Safety Reports - StockInvest.us
Neurocrine Biosciences shares fall amid Vykat safety concerns - Yahoo Finance
Neurocrine Biosciences stock falls on Vykat safety concerns By Investing.com - Investing.com Canada
Neurocrine Biosciences stock falls on Vykat safety concerns - Investing.com
Neurocrine study shows Ingrezza improved tardive dyskinesia symptoms - Investing.com
Neurocrine's INGREZZA Study Reports Better Daily Function in TD - Stock Titan
Why is Neurocrine Biosciences stock down today? By Investing.com - Investing.com Australia
Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Liquidity Mapping Around (NBIX) Price Events - Stock Traders Daily
Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing? - Sahm
Neurocrine Initiates Phase I Trial of Triple Agonist NBIP-’1968 for Obesity - BioPharma APAC
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com
Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Neurocrine Biosciences, Inc. (NB3.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeat
Healthcare Stocks Investors Are Watching For Steady Demand After Weak US Jobs Data - Sahm
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors - simplywall.st
Neurocrine starts phase 1 trial of obesity drug candidate - Investing.com
Neurocrine’s Investigational Obesity Drug Targets Three Receptors - Stock Titan
Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC - MarketBeat
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist - PR Newswire
Zacks Research Downgrades Neurocrine Biosciences (NASDAQ:NBIX) to Hold - MarketBeat
Neurocrine Biosciences (NBIX) CSO Jude Onyia makes bona fide stock gift - Stock Titan
0.43%
0.27%
자본화:
|
볼륨(24시간):